The Top Line Inside Foresight’s mission to redefine cancer monitoring (Sponsored)
Nov 17, 2025
In this engaging conversation, Jake Chabon, Co-founder and CEO of Foresight Diagnostics, and Dr. Max Diehn, Scientific Advisor and Stanford professor, dive into the groundbreaking world of minimal residual disease (MRD) detection. They unveil Foresight's PhasED-Seq technology, which can identify cancer traces down to parts per ten million, and discuss its potential to transform cancer monitoring. The duo explores biopharma collaborations and the future of MRD testing in precision medicine. Expect fascinating insights on how MRD could redefine oncology surveillance!
AI Snips
Chapters
Transcript
Episode notes
Clinic Frustration Sparked The Company
- Max recounts treating early-stage lung cancer patients where he could not tell who was cured and who would recur after treatment.
- That clinical uncertainty motivated his lab work on MRD and led to the phased-seq technology behind Foresight.
Best Use: Test-For-Cure And Scan Clarification
- MRD is most useful as a post-treatment 'test for cure' to decide who needs adjuvant therapy and who does not.
- Foresight's CLARITY assay aided guideline inclusion by resolving ambiguous PET-CT findings in DLBCL.
Sensitivity Plus Evidence-As-A-Strategy
- Foresight differentiates by ultra‑sensitive PhasED-Seq and a partnership-driven strategy to generate clinical utility.
- They prioritized peer-reviewed evidence first, then MRD-driven prospective trials to drive guideline and payer adoption.